SOUTH SAN FRANCISCO, Calif., Dec. 6, 2010 /PRNewswire/ —
diaDexus, Inc. (OTC Bulletin Board:
DDXS), a diagnostics company focused on the development and
commercialization of patent-protected in vitro diagnostic
products addressing unmet needs in cardiovascular disease, today
said that it plans to present at the Canaccord Genuity 5th Annual
Cardiovascular, Diabetes & Obesity Conference on Tuesday,
December 7, 2010 at 1:30 pm Pacific Time (4:30 pm Eastern Time) at
the Nikko Hotel in San Francisco, CA.
Patrick Plewman, Chief Executive Officer of diaDexus, will
provide a corporate overview presentation. To access the live
webcast and the subsequent archived recording of the presentation,
please log onto diaDexus’ website at www.diadexus.com/webcast.
About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, is
focused on the development and commercialization of
patent-protected in vitro diagnostic products addressing
unmet needs in cardiovascular disease. The company’s PLAC ELISA
Test for Lp-PLA2 is the only blood test cleared by the FDA to aid
in assessing risk for both coronary heart disease and ischemic
stroke associated with atherosclerosis. For more information,
please visit the company’s website at www.diaDexus.com
‘/>”/>
